Mylan’s Wixela is ‘imminent’

Mylan believes that US Food and Drug Administration (FDA) approval of its Wixela Inhub generic alternative to GlaxoSmithKline’sAdvair Diskus (fluticasone/salmeterol) respiratory blockbuster is “imminent”. “Mylan confirms it has not received any new information request or complete response letter (CRL) from the FDA,” the company said in a statement issued on 22 October.